ReviewCancer immunity2012
Translating basic mechanisms of IgG effector activity into next generation cancer therapies.
Review in Cancer immunity, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 85 citations in OpenAlex.
- Evaluation of acylated/deacylated ghrelin, CCL20/CCR6 concentration, and IgG N-Glycan alterations in different dysplasia grades of colon adenoma.Glycoconjugate journal · 2026Article
- Molecular determinants of sialylated IgG anti-inflammatory activity.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Mixed IgG Fc immune complexes exhibit blended binding profiles and refine FcR affinity estimates.Cell reports · 2023Article
- Roles and mechanisms of tumour-infiltrating B cells in human cancer: a new force in immunotherapy.Biomarker research · 2023Review
- Mixed IgG Fc immune complexes exhibit blended binding profiles and refine FcR affinity estimates.bioRxiv : the preprint server for biology · 2023Article
- An antibody Fc engineered for conditional antibody-dependent cellular cytotoxicity at the low tumor microenvironment pH.The Journal of biological chemistry · 2022Article
- Review
- Article
- Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs.Cancers · 2021Review
- Antibodies targeting sialyl Lewis A mediate tumor clearance through distinct effector pathways.The Journal of clinical investigation · 2019Article
- Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.Journal for immunotherapy of cancer · 2019Article
- Deciphering Fc-mediated Antiviral Antibody Functions in Animal Models.Frontiers in immunology · 2019Review
- Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein.Molecular cancer therapeutics · 2018Article
- Evolution of Neutralization Response in HIV-1 Subtype C-Infected Individuals Exhibiting Broad Cross-Clade Neutralization of HIV-1 Strains.Frontiers in immunology · 2018Article
- Effects of N-Glycan Composition on Structure and Dynamics of IgG1 Fc and Their Implications for Antibody Engineering.Scientific reports · 2017Article
- IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions.Nature immunology · 2017Article
- Exploring Site-Specific N-Glycosylation of HEK293 and Plant-Produced Human IgA Isotypes.Journal of proteome research · 2017Article
- Therapeutic antibody targeting of indoleamine-2,3-dioxygenase (IDO2) inhibits autoimmune arthritis.Clinical immunology (Orlando, Fla.) · 2017Article
- Immunoregulatory functions of immune complexes in vaccine and therapy.EMBO molecular medicine · 2016Review
- Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions.Journal of immunology (Baltimore, Md. : 1950) · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monoclonal antibodies of the immunoglobulin G (IgG) isotype have become a well-established therapeutic tool for the targeting of malignant cells in tumor patients. Despite tremendous success in the treatment of lymphoma and breast cancer, it has also become clear that we may not be able to further improve antibody therapy of cancer by simply generating more tumor-specific antibodies with a higher affinity. Instead, the work of many groups in the past years suggests that optimizing the recruitment of effector functions provided by the adaptive and innate immune systems via engineering of the IgG constant domain may hold great promise to achieve enhanced therapeutic activities. A major goal in cancer therapy would be to initiate adaptive immune responses to the patient's tumor that would result in long-term protection against recurrence. The use of immunostimulatory antibodies shows great promise in stimulating adaptive immune responses. Surprisingly, recent studies also implicate an important role for the antibody constant domain in the activity of these molecules in vivo, opening up new possibilities to further improve the activity of immunomodulatory antibodies by Fc engineering.
Indexed as
Identifiers
22896758PMC3380343W2165437317What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.